Axsome Therapeutics Inc
AXSM
Market Cap$3.52B
Close$
$63.93
13.8% downside
Current Fair Value
13.8% downsideOvervalued by 13.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.52 Billion |
|---|---|
| Enterprise Value | $3.32 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-5.27 |
| Beta | 0.93 |
| Outstanding Shares | 47,493,320 |
| Avg 30 Day Volume | 526,305 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -14.73 |
|---|---|
| PEG | -24.11 |
| Price to Sales | 14.84 |
| Price to Book Ratio | 18.55 |
| Enterprise Value to Revenue | 12.26 |
| Enterprise Value to EBIT | -18.13 |
| Enterprise Value to Net Income | -14 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.94 |
Revenue Sources
No data
ESG Score
No data
About Axsome Therapeutics Inc
CEO: Herriot Tabuteau Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For the many people facing unsatisfactory tre...